Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group
Φόρτωση...
Ημερομηνία
Συγγραφείς
Pectasides, D.
Samantas, E.
Fountzilas, G.
Briasoulis, E.
Kosmidis, P.
Skarlos, D.
Dimopoulos, M. A.
Kalofonos, H. P.
Economopoulos, T.
Syrigos, K.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Lung Cancer
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
OBJECTIVE: The purpose of this study was to evaluate the efficacy and toxicity of cisplatin, etoposide and irinotecan as first-line treatment in patients with extensive small-cell lung cancer (E-SCLC). PATIENTS AND METHODS: Chemo-naive adult patients with a performance status (PS) of 0-2 and adequate organ function were eligible. Patients received cisplatin 20mg/m(2) i.v. daily for three consecutive days, etoposide 75mg/m(2) i.v. daily for three consecutive days and irinotecan 120mg/m(2) i.v. on day 2, every 21 days for six to eight cycles. Administration of G-CSF was given in the presence of febrile neutropenia and as a 5-day prophylaxis around the recorded nadir day in patients who developed grades 3-4 neutropenia. RESULTS: Fifty-six patients were assessable. The median age was 62.2 years; 96.4% had PS 0-1, 33.5% had >3 metastatic sites. The overall response rate was 80.4% with 8 (14.3%) patients achieving a complete response. The median time to tumor progression was 7.8 months [95% confidence interval (CI), 7.1-8.6 months] with a median survival of 15.1 months [95% CI, 9.7-20.5 months] and 1-year survival rate of 56.5%. One patient died from toxicity. Grades 3-4 neutropenia occurred in 37.5% of patients, grades 3-4 thrombocytopenia occurred in 10.9% of patients and 11 (19.6%) patients developed febrile neutropenia. Grades 3-4 non-hematological toxicities were primarily nausea-vomiting 3.6%, diarrhea 7.1% and fatigue 3.6%. CONCLUSION: This study strongly suggests that cisplatin, etoposide and irinotecan combination is very effective for the treatment of E-SCLC with good safety profile. The triplet regimen currently seems a promising regimen and has to be further explored in phase III trials.
Περιγραφή
Λέξεις-κλειδιά
Adult, Aged, Camptothecin/adverse effects/*analogs & derivatives/therapeutic use, Carcinoma, Small Cell/*drug therapy/pathology, Cisplatin/adverse effects/*therapeutic use, Disease Progression, Dose-Response Relationship, Drug, Drug Therapy, Combination, Etoposide/adverse effects/*therapeutic use, Female, Humans, Lung Neoplasms/*drug therapy/pathology, Male, Middle Aged, Survival Rate
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/17698241
http://ac.els-cdn.com/S016950020700400X/1-s2.0-S016950020700400X-main.pdf?_tid=6fda7be28bdd84412d029e4e6eb44bf7&acdnat=1333703544_dd61f8cad53cb795221b0d9e25bb4862
http://ac.els-cdn.com/S016950020700400X/1-s2.0-S016950020700400X-main.pdf?_tid=6fda7be28bdd84412d029e4e6eb44bf7&acdnat=1333703544_dd61f8cad53cb795221b0d9e25bb4862
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής